Publications by authors named "Chong Lee Ng"
Since the advent of hybridoma technology in the year 1975, it took a decade to witness the first approved monoclonal antibody Orthoclone OKT39 (muromonab-CD3) in the year 1986. Since then, continuous strides have been made to engineer antibodies for specific desired effects. The engineering efforts were not confined to only the variable domains of the antibody but also included the fragment crystallizable (Fc) region that influences the immune response and serum half-life.
View Article and Find Full Text PDFArticle Synopsis
- - Ebola virus causes severe and often fatal hemorrhagic fever, leading to urgent needs for effective diagnosis and treatment, with two monoclonal antibodies approved by the USFDA for EVD.
- - Research focuses on targeting the Ebola virus protein VP35, which could enhance treatment efforts and has been studied using three isolated mAb clones that bind to it in vitro, demonstrating their potential to inhibit VP35 function.
- - Structural modeling was performed to analyze how these antibodies interact with VP35, providing insights that could aid in designing new monoclonal antibodies using computational methods in future therapeutic developments.